Levy Noah G.'s Form 4 filing
Merrimack Pharmaceuticals Inc (MACK) · filed Jan 4, 2023
- Accession no.
- 0000899243-23-000580
- Filed
- Jan 4, 2023, 4:06 PM ET
- Trade date
- Dec 30, 2022-Jan 3, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $74.2K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Levy Noah G.CIK 0001788608 | Director, Other: See remarks |
| Newtyn Partners, LPCIK 0001548707 | Other: See Remarks |
| Newtyn TE Partners, LPCIK 0001548709 | Other: See Remarks |
| Newtyn Management, LLCCIK 0001569241 | Other: See Remarks |
| Newtyn Capital Partners, LPCIK 0001789643 | Other: See Remarks |
| Ledo Capital, LLCCIK 0001789647 | Other: See Remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2022 | Common Stock | PPurchaseAcquired | +1,300 | $11.24 | +$14,614.99 | 1,014,286 | Indirect | |
| Jan 3, 2023 | Common Stock | PPurchaseAcquired | +5,300 | $11.24 | +$59,563.52 | 1,019,586 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.